Biosimilars are biologic products that are highly similar to an approved reference product, with no clinically meaningful differences in quality, safety, and efficacy. They are developed through a rigorous comparability exercise, including analytical, non-clinical, and clinical studies, to confirm equivalence to the originator.

Developed by Biocon, these biosimilars support broader patient access to biologic therapies while maintaining established clinical performance.